Levosimendan and Weaning From VA-ECMO

Affiliations

Mark H Drazner. JAMA. 2026.

. 2026 Jan 6;335(1):33-34.

doi: 10.1001/jama.2025.20299.

¹ Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.

No abstract available

Comment in

Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial.
Combes A, Saura O, Nesseler N, Lebbah S, Rozec B, Levy B, Fellahi JL, Beurton A, Meslin S, Gaudard P, Bouglé A, Vincentelli A, Sonneville R, Lebreton G, Lévy D, Ouattara A, Tubach F; LEVOECMO Trial Group and the International ECMO Network (ECMONet). Combes A, et al. JAMA. 2026 Jan 6;335(1):60-69. doi: 10.1001/jama.2025.19843. JAMA. 2026. PMID: 41324946 Clinical Trial.